vimarsana.com
Home
Live Updates
Second-Line Fruquintinib Plus Paclitaxel Significantly Improves PFS But Not OS in Advanced Gastric or GEJ Adenocarcinoma : vimarsana.com
Second-Line Fruquintinib Plus Paclitaxel Significantly Improves PFS But Not OS in Advanced Gastric or GEJ Adenocarcinoma
Fruquintinib/paclitaxel significantly improved PFS but not OS vs paclitaxel alone in the second-line treatment in patients with advanced gastric cancer.
Related Keywords
China ,
Guangzhou ,
Guangdong ,
Junshi Biosciences ,
Astellas Pharma ,
Rui Hua Xu ,
Merck Serono ,
Sun Yat Sen University Cancer Center ,
Bristol Myers Squibb ,
Astrazeneca ,
Phase 3 Frutiga Study Nct03223376 ,
February 2024 Asco Plenary Series ,
Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma ,
Fruquintinib ,
Fruzaqla ,
vimarsana.com © 2020. All Rights Reserved.